MX2023013849A - Metodos para el tratamiento de diabetes autoinmunitaria post-infecciosa. - Google Patents

Metodos para el tratamiento de diabetes autoinmunitaria post-infecciosa.

Info

Publication number
MX2023013849A
MX2023013849A MX2023013849A MX2023013849A MX2023013849A MX 2023013849 A MX2023013849 A MX 2023013849A MX 2023013849 A MX2023013849 A MX 2023013849A MX 2023013849 A MX2023013849 A MX 2023013849A MX 2023013849 A MX2023013849 A MX 2023013849A
Authority
MX
Mexico
Prior art keywords
post
treatment
methods
autoimmune diabetes
infectious autoimmune
Prior art date
Application number
MX2023013849A
Other languages
English (en)
Spanish (es)
Inventor
Francisco Leon
Original Assignee
Provention Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Provention Bio Inc filed Critical Provention Bio Inc
Publication of MX2023013849A publication Critical patent/MX2023013849A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
MX2023013849A 2021-05-24 2022-05-24 Metodos para el tratamiento de diabetes autoinmunitaria post-infecciosa. MX2023013849A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163192414P 2021-05-24 2021-05-24
PCT/US2022/030780 WO2022251258A1 (en) 2021-05-24 2022-05-24 Methods for treating post infectious autoimmune diabetes
US17/752,650 US20220372146A1 (en) 2021-05-24 2022-05-24 Methods for treating post infectious autoimmune diabetes

Publications (1)

Publication Number Publication Date
MX2023013849A true MX2023013849A (es) 2023-12-08

Family

ID=84104472

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023013849A MX2023013849A (es) 2021-05-24 2022-05-24 Metodos para el tratamiento de diabetes autoinmunitaria post-infecciosa.

Country Status (10)

Country Link
US (1) US20220372146A1 (cg-RX-API-DMAC7.html)
EP (1) EP4347021A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024521164A (cg-RX-API-DMAC7.html)
KR (1) KR20240023522A (cg-RX-API-DMAC7.html)
CN (1) CN117794572A (cg-RX-API-DMAC7.html)
AU (1) AU2022283272A1 (cg-RX-API-DMAC7.html)
CA (1) CA3219473A1 (cg-RX-API-DMAC7.html)
IL (1) IL308627A (cg-RX-API-DMAC7.html)
MX (1) MX2023013849A (cg-RX-API-DMAC7.html)
WO (1) WO2022251258A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023013851A (es) 2021-05-24 2023-12-08 Provention Bio Inc Metodos para el tratamiento de diabetes tipo 1.
US20230382993A1 (en) * 2022-05-24 2023-11-30 Provention Bio, Inc. Methods and compositions for preventing or delaying type 1 diabetes
TW202506177A (zh) * 2023-03-30 2025-02-16 美商普泛森生技公司 減少外源性胰島素使用之方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005213449A1 (en) * 2004-02-04 2005-08-25 The La Jolla Institute For Allergy And Immunology Anti-CD3 and antigen-specific immunotherapy to treat autoimmunity
US20090142338A1 (en) * 2005-03-04 2009-06-04 Curedm, Inc. Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions
JP2009544761A (ja) * 2006-06-14 2009-12-17 マクロジェニクス,インコーポレーテッド 低毒性免疫抑制モノクローナル抗体を用いて自己免疫疾患を治療する方法
WO2015073833A1 (en) * 2013-11-15 2015-05-21 Pharmacyclics, Inc. Methods for delaying or preventing the onset of type 1 diabetes
JP7137696B2 (ja) * 2019-05-14 2022-09-14 プロヴェンション・バイオ・インコーポレイテッド 1型糖尿病を予防するための方法および組成物
WO2021035054A1 (en) * 2019-08-20 2021-02-25 Precision Biosciences, Inc. Lymphodepletion dosing regimens for cellular immunotherapies
KR20230092863A (ko) * 2020-06-11 2023-06-26 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
MX2023013851A (es) * 2021-05-24 2023-12-08 Provention Bio Inc Metodos para el tratamiento de diabetes tipo 1.
US20230382993A1 (en) * 2022-05-24 2023-11-30 Provention Bio, Inc. Methods and compositions for preventing or delaying type 1 diabetes

Also Published As

Publication number Publication date
JP2024521164A (ja) 2024-05-28
US20220372146A1 (en) 2022-11-24
CA3219473A1 (en) 2022-12-01
WO2022251258A1 (en) 2022-12-01
IL308627A (en) 2024-01-01
AU2022283272A1 (en) 2023-12-07
EP4347021A4 (en) 2025-04-23
EP4347021A1 (en) 2024-04-10
CN117794572A (zh) 2024-03-29
KR20240023522A (ko) 2024-02-22

Similar Documents

Publication Publication Date Title
MX2023013851A (es) Metodos para el tratamiento de diabetes tipo 1.
MX2021009622A (es) Metodos para tratar la colestasis.
ECSP21080535A (es) Compuestos y métodos para el tratamiento de covid-19
CL2024000466A1 (es) Métodos de tratamiento de la insuficiencia cardíaca mediante la administración de omecamtiv mecarbil
CL2025000279A1 (es) Arn para prevenir o tratar tuberculosis
MX2022000143A (es) Metodos novedosos.
MX2023002024A (es) Métodos de tratamiento con modulador de miosina.
CO2022013777A2 (es) Uso de agentes para el tratamiento de condiciones respiratorias
CO2020013600A2 (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak
AR083878A1 (es) Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
MX2020006284A (es) Tetratiomolibdato de bis-colina para tratar la enfermedad de wilson.
AR120399A1 (es) Un método de tratamiento de un cáncer positivo para dll3
MX2024005237A (es) Compuesto que tiene actividad de degradacion de la proteina btk, y usos medicos del mismo.
RU2017116973A (ru) Способы применения и композиции нейрегулинов для предотвращения, лечения или замедления сердечной недостаточности с сохраненной фракцией выброса
CL2023000943A1 (es) Formas cristalinas de un compuesto farmacéutico.
AR122127A1 (es) VACUNA DE b-AMILOIDE PARA EL TRATAMIENTO DE LA ENFERMEDAD DE ALZHEIMER
AR119033A1 (es) Métodos para tratar cánceres asociados con virus con inhibidores de la histona deacetilasa
MX2023000187A (es) Dosificacion de vibegron para el tratamiento de vejiga sobreactiva.
MX2025011577A (es) Metodos para la reduccion del uso de insulina exogena
CL2023003841A1 (es) Trampas de ligando del factor de crecimiento transformante beta para el tratamiento de enfermedades
AR119430A1 (es) Métodos para tratar o prevenir la atrofia muscular espinal
CO2026005447A2 (es) Compuesto de glp-1, y método de preparación y uso del mismo
MX391376B (es) Composiciones de la membrana de la cáscara del huevo para usarse en el tratamiento de la cadena ligera kappa del factor nuclear de las células b activadas (nf-kb) en un organismo hospedero.
CO2025018532A2 (es) Un método para el tratamiento de tumores sólidos con un conjugado anticuerpo-fármaco dirigido a claudina 18.2
MX2025002875A (es) Un gip/glp1 para usar en terapia